Prof. Ji Zhu 朱骥
Chief Physician, Professor
Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Combined radiotherapy and chemotherapy for abdominal and pelvic tumors, especially gastrointestinal cancers. Focuses on preoperative and postoperative care, palliative treatment for advanced stages, and sphincter-preserving strategies for low rectal cancer after chemoradiotherapy.
Dr. Zhu is a Chief Physician, Professor, and Doctoral Supervisor.
Professional roles
- Chair-elect, Radiation Therapy Committee, Zhejiang Anti-Cancer Association
- Standing Committee Member, Young Experts Committee, Chinese Society of Clinical Oncology (CSCO)
- Deputy Leader, Radiotherapy Group, Colorectal Cancer Committee, China Anti-Cancer Association
- Secretary-General, Radiation Therapy Committee, Shanghai Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhu Ji). Papers usually list the name as Ji Zhu or Zhu J.
Selected publications
42 papers on PubMed matched by name and affiliation; 23 as first or senior author since 2016. Most recent first- or senior-author papers:
- Radiother Oncol, 2026 (senior author): Corrigendum to "Minimum sample size calculation for radiomics-based binary outcome prediction models: tutorial and practical example based on Riley et al's theoretical framework" [Radiother. Oncol. 212 (2025) 111134]. PubMed 42735486
- J Nanobiotechnology, 2026 (senior author): Rectal delivered nanocomposite suppository against radiation-induced proctitis. PubMed 41634832
- Phytomedicine, 2025 (senior author): Dendrobium huoshanense flavone attenuates radiation enteritis by enhancing gut immunity to inhibit inflammation and fibrosis. PubMed 41075521
- Radiother Oncol, 2025 (senior author): Minimum sample size calculation for radiomics-based binary outcome prediction models: Theoretical framework and practical example. PubMed 40930280
- Cancer Commun (Lond), 2025 (senior author): Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial. PubMed 40899645
- Mol Cancer, 2025 (senior author): Reprogramming cellular senescence and aging clocks for advanced cancer immunotherapy. PubMed 41039629
- Adv Sci (Weinh), 2025 (senior author): Patients-Derived Organoids Sequencing-based FOXP4 Facilitates Radioresistance by Transcriptionally Modifying GPX4 to Regulate ferroptosis in Colorectal Cancer. PubMed 40789053
- Cancer Lett, 2025 (senior author): Distinct immunophenotypic profiles and neutrophil heterogeneity in colorectal cancer. PubMed 39993650
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion